279 related articles for article (PubMed ID: 25700719)
21. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
[TBL] [Abstract][Full Text] [Related]
22. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
23. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S
Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
[TBL] [Abstract][Full Text] [Related]
24. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
Vandekerckhove L; Verhofstede C; Demecheleer E; De Wit S; Florence E; Fransen K; Moutschen M; Mostmans W; Kabeya K; Mackie N; Plum J; Vaira D; Van Baelen K; Vandenbroucke I; Van Eygen V; Van Marck H; Vogelaers D; Geretti AM; Stuyver LJ
J Antimicrob Chemother; 2011 Feb; 66(2):265-72. PubMed ID: 21196489
[TBL] [Abstract][Full Text] [Related]
25. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G; Nelson M; Lazzarin A; Konourina I; Hoepelman AI; Lampiris H; Hirschel B; Tebas P; Raffi F; Trottier B; Bellos N; Saag M; Cooper DA; Westby M; Tawadrous M; Sullivan JF; Ridgway C; Dunne MW; Felstead S; Mayer H; van der Ryst E;
N Engl J Med; 2008 Oct; 359(14):1442-55. PubMed ID: 18832245
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
Bocket L; Peytavin G; Alidjinou EK; Ajana F; Choisy P; Lê M; Charpentier C; Descamps D; Yazdanpanah Y; Katlama C; Simon A; Calvez V; Marcelin AG; Soulie C
J Antimicrob Chemother; 2016 Sep; 71(9):2651-3. PubMed ID: 27234463
[TBL] [Abstract][Full Text] [Related]
27. Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods.
Kalu AW; Telele NF; Aralaguppe SG; Gebre-Selassie S; Fekade D; Marrone G; Sonnerborg A
Curr HIV Res; 2018; 16(2):113-120. PubMed ID: 29766813
[TBL] [Abstract][Full Text] [Related]
28. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
Kagan RM; Johnson EP; Siaw M; Biswas P; Chapman DS; Su Z; Platt JL; Pesano RL
PLoS One; 2012; 7(9):e46334. PubMed ID: 23029482
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
Rodriguez C; Soulié C; Marcelin AG; Calvez V; Descamps D; Charpentier C; Flandre P; Recordon-Pinson P; Bellecave P; Pawlotsky JM; Masquelier B;
PLoS One; 2015; 10(6):e0127816. PubMed ID: 26068869
[TBL] [Abstract][Full Text] [Related]
31. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Perry CM
Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
[TBL] [Abstract][Full Text] [Related]
32. The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.
van Lelyveld SF; Wensing AM; Hoepelman AI
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1241-7. PubMed ID: 23113664
[TBL] [Abstract][Full Text] [Related]
33. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
Charpentier C; Joly V; Larrouy L; Fagard C; Visseaux B; de Verdière NC; Raffi F; Yeni P; Descamps D;
J Antimicrob Chemother; 2013 Mar; 68(3):690-6. PubMed ID: 23152480
[TBL] [Abstract][Full Text] [Related]
34. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
McGovern RA; Thielen A; Mo T; Dong W; Woods CK; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
AIDS; 2010 Oct; 24(16):2517-25. PubMed ID: 20736814
[TBL] [Abstract][Full Text] [Related]
35. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Soulié C; Assoumou L; Darty M; Rodriguez C; Donati F; Sayon S; Peytavin G; Valantin MA; Caby F; Schneider L; Canestri A; Costagliola D; Katlama C; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2015 Dec; 70(12):3339-44. PubMed ID: 26396157
[TBL] [Abstract][Full Text] [Related]
36. HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
Visseaux B; Charpentier C; Rouard C; Fagard C; Glohi D; Tubiana R; Damond F; Brun-Vézinet F; Matheron S; Descamps D;
AIDS; 2014 Sep; 28(14):2160-2. PubMed ID: 25265081
[TBL] [Abstract][Full Text] [Related]
37. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
[TBL] [Abstract][Full Text] [Related]
38. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
[TBL] [Abstract][Full Text] [Related]
39. Treatment of HIV infection with the CCR5 antagonist maraviroc.
Kromdijk W; Huitema AD; Mulder JW
Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
[TBL] [Abstract][Full Text] [Related]
40. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
Poveda E; Hernández-Quero J; Pérez-Elías MJ; Ribas MA; Martínez-Madrid OJ; Flores J; Navarro J; Gutiérrez F; García-Deltoro M; Imaz A; Ocampo A; Artero A; Blanco F; Bernal E; Pasquau J; Mínguez-Gallego C; Pérez N; Aiestaran A; García F; Paredes R;
HIV Med; 2017 Aug; 18(7):482-489. PubMed ID: 28035758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
